Targeted therapy in colorectal cancer

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 2, 2006, Pages 124-132

  Rajpal, Supriya ^a   Venook, Alan P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of Medical Oncology ^*

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Vascular endothelial growth factor

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; AZD 2171; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GROWTH FACTOR; IMC 1121B; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SUTINIB MALATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VATALANIB; WARFARIN; ZACTIMA;

ACNE; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG APPROVAL; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HEMATEMESIS; HEMOPTYSIS; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MONOTHERAPY; NEUTROPENIA; PROTEIN EXPRESSION; SEPSIS; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645330146     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-1047.
4. Kohne C, Van Cutsem E, Wils J, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986. Proc Am Soc Clin Oncol. 2003;22:254a.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
6. Goldberg RM, Sargent DJ, Morton RF, et al. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol. 2004;22:23-30.
7. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2002;21:129a.
8. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan versus fluorouracil by continuous nifusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
9. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
10. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients eith progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003;21:2059-2069.
11. Grothey A, Sargent D, Goldberg PM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves eith the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
12. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
13. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974;19:331-358.
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
15. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73-80.
16. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
17. Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc). 2003;39(suppl C):81-93.
18. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factorr acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;I:1024-1028.
19. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
20. Frank RE, Saclarides TJ, Leurgans S, et al. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg. 1995;222:695-699.
21. Choi HJ, Hyun MS, Jung GJ, et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastatic and recurrence. Oncology. 1998;55:575-581.
22. Ellis L. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol. 2004;31(6 suppl 17):3-9.
23. Borgstrom P, Gold DP, Hillan KJ, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999;19:4203-4214.
24. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastatic. J Clin Invest. 1995;95:1789-1797.
25. Hurwitz H, Feherenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
26. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002;94:1484-1493.
27. Jayson GC, Mulatero C, Ranson M et al. Anti-VEGF antibody HuMV833: an EORTC biological treatment development group phase I toxicity, pharmacokinetic and pharmacodynamic study. Proc Am Soc Clin Oncol. 2001:14a.
28. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
29. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
30. Kabbinavar FF, Schulz J, McCleod M et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol. 2004;23:249a.
31. Hurwitz H, Fehrenbacher L, Hainsworch J, et al. Bevacizumab in combination with 5-fluorouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2004:182a.
32. Giantonio BJ, Catalano PJ, Meropol NJ. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol. 2005:169a.
33. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol. 2005:2a.
34. Hochster HS, Welles L, Hart L et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized TREE-2 trial. Proc Am Soc Clin Oncol. 2005:241a.
35. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol. 2004;22:1198.
36. Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc Am Soc Clin Oncol. 2004;22:3528a.
37. Hambleton J, Skillings J, Kabbinavar F, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pt) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2005:3554a.
38. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004;54(suppl 1):S32-39.
39. Scappaticci F, Fehrenbacher L, Cartwright T, et al. Analysis of wound healing and bleeding post-surgery in metastaric colorectal cancer patients treated with bevacizumab. Proc Am Soc Clin Oncol. 2004:235a.
40. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplattn and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184-2191.
41. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Gmup (ECOG) trial - E4599. Proc Am Soc Clin Oncol. 2005:Abstract LBA4.
42. Tabernero J, Salazar R, Casado E, Martinelli F, Gomez P, Baselga J. Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol. 2004;15(suppl 4):iv55-iv62.
43. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucavorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol. 2005:Abstract LBA3.
44. Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol. 2004;31(suppl 17):10-16.
45. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637-643.
46. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growdi factor receptor by immunohistochemistry. J Clin Oncol. 2005;9:1803-1810.
47. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
48. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
49. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001;7:2958-2970.
50. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10:250-261.
51. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol. 2001;20:2a.
52. Folprecht G, Lutz M, Schoeffski P, et al. Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol. 2004:283a.
53. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): preliminary results. Proc Am Soc Clin Oncol. 2004:3512a.
54. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol. 2004:3513a.
55. Lordick F, Arnold D, Hoehler T, et al. Cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (MCRC) expressing epidermal growth factor receptor (EGFR): results of a multicenter phase I/II study. Proc Am Soc Clin Oncol. 2005:247a.
56. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol. 2002:536a.
57. Badarinath S, Mitchell EP, Jennis A, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary safety analysis of a randomized phase III trial. Proc Am Soc Clin Oncol. 2004;22:3531a.
58. Lenz H, Mayer RJ, Gold P, et al. Activity of Erbitux (cetuximab) in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin. Proc Am Soc Clin Oncol. 2005:225a.
59. Mirtsching B, Cichon J, Beasley S, et al. Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patient and disease variables. Proc Am Soc Clin Oncol. 2005:3671a.
60. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. Proc Am Soc Clin Oncol. 2005:3551a.
61. Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol. 2005:169b.
62. Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.